» Articles » PMID: 17012456

Annual Costs Associated with Diagnosis of Uterine Leiomyomata

Overview
Journal Obstet Gynecol
Date 2006 Oct 3
PMID 17012456
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To describe the annual care, direct health care, and indirect work loss costs for women with a diagnosis of uterine leiomyomata.

Methods: We examined data from an employer claims database of 1.2 million beneficiaries (1999 to 2003). Analysis was restricted to women with at least 12 months of continuous coverage and ages 18 to 64 years with at least one diagnosis of leiomyomata (International Classification of Diseases, 9th Revision, 218.xx, 654.1x). We selected a comparison group of women without a leiomyoma diagnosis using a 1:1 match on age, employment, region, health plan type, and length of enrollment. We compared resource use, disability claims, and excess costs in the year after the index diagnosis.

Results: The average age of women diagnosed with leiomyomata in this study was 43.7 years. Women with leiomyomata (N = 5,122) had more clinic visits (relative risk [RR] 1.2, 95% confidence interval [CI] 1.2-1.2), diagnostic tests (RR 3.1, 95% CI 2.9-3.2), and procedures (RR 34.6, 95% CI 25.8-46.5) than controls (N = 5,122). Within 1 year of the diagnosis of leiomyomata, 42% of women had a complete blood count, 66% had pelvic imaging, and 30% had surgery (68% of surgical procedures involved hysterectomy). Women with leiomyomata were 3-fold more likely to have disability claims (RR 3.1, 95% CI 2.7-3.6). Estimated average annual excess cost for each woman with leiomyomata (adjusted for confounders) was Dollars 4,624 (Dollars 771 in work loss costs). Total costs for women with leiomyomata were 2.6 times greater than for controls.

Conclusion: Diagnosed uterine leiomyomata are associated with increased resource use and with substantially higher health care and work loss costs.

Level Of Evidence: II-3.

Citing Articles

Treatment With Antitumor Agents Recommended by Cancer Genome Panel for Uterine Leiomyosarcoma.

Hayashi T, Kishimoto N, Abiko K, Konishi I J Clin Med Res. 2024; 15(10-11):461-468.

PMID: 38189037 PMC: 10769602. DOI: 10.14740/jocmr5052.


Genome-wide causal mediation analysis identifies genetic loci associated with uterine fibroids mediated by age at menarche.

Tai A, Lin R, Lin Y, Wang C, Lin S, Imoto S Hum Reprod. 2022; 37(9):2197-2212.

PMID: 35689443 PMC: 10467635. DOI: 10.1093/humrep/deac136.


Health Care Costs and Treatment Patterns Associated with Uterine Fibroids and Heavy Menstrual Bleeding: A Claims Analysis.

Wang A, Wang S, Owens C, Vora J, Diamond M J Womens Health (Larchmt). 2021; 31(6):856-863.

PMID: 34591695 PMC: 9245789. DOI: 10.1089/jwh.2020.8983.


Uterine artery embolization, surgery and high intensity focused ultrasound in the treatment of uterine fibroids: a network meta-analysis.

Gao H, Li T, Fu D, Wei J Quant Imaging Med Surg. 2021; 11(9):4125-4136.

PMID: 34476193 PMC: 8339645. DOI: 10.21037/qims-20-1331.


Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women.

Fischer N, Nieuwenhuis T, Singh B, Yenokyan G, Segars J J Clin Endocrinol Metab. 2020; 106(2):e650-e659.

PMID: 33035320 PMC: 7823233. DOI: 10.1210/clinem/dgaa718.